The cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer

Annals of Oncology

Volumn 23, Issue 6, 2012, Pages 1455-1464

  LaBonte, M J ^a   Wilson, P M ^b   Yang, D ^b   Zhang, W ^a   Ladner, R D ^b   Ning, Y ^a   Gerger, A ^a   Bohanes, P O ^a   Benhaim, L ^a   El khoueiry, R ^a   El khoueiry, A ^a   Lenz, H J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Capecitabine; Cyclin D1; Lapatinib; Metastatic breast cancer; Polymorphisms

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CAPECITABINE; CYCLIN D1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INTERLEUKIN 8; LAPATINIB; THYMIDYLATE SYNTHASE; TRASTUZUMAB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER PROGNOSIS; CYCLIN D1 GENE; DNA EXTRACTION; EPIDERMAL GROWTH FACTOR GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN EPIDERMAL RECEPTOR 2 GENE; INTERLEUKIN 8 GENE; MAJOR CLINICAL STUDY; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; MONOTHERAPY; ONCOGENE; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; THYMIDYLATE SYNTHASE GENE; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE;

EID: 84861728254     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr445     Document Type: Article

References (38)

1. McPherson K, Steel CM, Dixon JM. ABC of breast diseases. Breast cancerepidemiology, risk factors, and genetics. BMJ 2000; 321: 624-628.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
3. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society 2010.
4. McCann AH, Dervan PA, O'Regan M et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991; 51: 3296-3303.
5. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
6. Menard S, Fortis S, Castiglioni F et al. HER2 as a prognostic factor in breast cancer. Oncology 2001; 61 (Suppl 2): 67-72.
7. Gullick WJ, Love SB, Wright C et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434-438.
8. Xia W, Mullin RJ, Keith BR et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002; 21: 6255-6263.
9. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
10. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
11. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
12. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
13. Press MF, Finn RS, Cameron D et al. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy inwomen with metastatic breast cancer. Clin Cancer Res 2008; 14: 7861-7870.
14. Spector NL, Xia W, Burris H III et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol 2005; 23: 2502-2512.
15. Rhee J, Han SW, Cha Y et al. High serum TGF-alpha predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. Breast Cancer Res Treat 2010; 125: 107-114.
16. Lurje G, Husain H, Power DG et al. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol 2010; 21: 78-86.
17. Lurje G, Zhang W, Schultheis AM et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008; 19: 1734-1741.
18. Lurje G, Nagashima F, Zhang W et al. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with singleagent cetuximab. Clin Cancer Res 2008; 14: 7884-7895.
19. Lurje G, Zhang W, Yang D et al. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 2008; 18: 161-168.
20. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and Regression Trees. New York: Chapman & Hall (Wadsworth, Inc) 1984.
21. Therneau TM, Atkinson EJ. An Introduction to Recursive Partitioning Using the RPART Routines. Rochester, MN: Mayo Clinic 1997; Technical Report no 61.
22. Kato J, Matsushime H, Hiebert SW et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331-342.
23. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
24. Pirkmaier A, Yuen K, Hendley J et al. Cyclin d1 overexpression sensitizes breast cancer cells to fenretinide. Clin Cancer Res 2003; 9: 1877-1884.
25. Ratschiller D, Heighway J, Gugger M et al. Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003; 21: 2085-2093.
26. Khoo ML, Beasley NJ, Ezzat S et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002; 87: 1814-1818.
27. Drobnjak M, Osman I, Scher HI et al. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000; 6: 1891-1895.
28. Holley SL, Parkes G, Matthias C et al. Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol 2001; 159: 1917-1924.
29. McKay JA, Douglas JJ, Ross VG et al. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Aberdeen Colorectal Initiative. Int J Cancer 2000; 88: 77-81.
30. Betticher DC, Thatcher N, Altermatt HJ et al. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11: 1005-1011.
31. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006; 25: 1620-1628.
32. Solomon DA, Wang Y, Fox SR et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003; 278: 30339-30347.
33. Li Z, Jiao X, Wang C et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 2010; 70: 8802-8811.
34. Pabalan N, Bapat B, Sung L et al. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2008; 17: 2773-2781.
35. Kunnumakkara AB, Diagaradjane P, Anand P et al. Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. Int J Cancer 2009; 125: 2187-2197.
36. Gautschi O, Hugli B, Ziegler A et al. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 2006; 51: 303-311.
37. Zhang W, Gordon M, Press OA et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16: 475-483.
38. Zhang W, Azuma M, Lurje G et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 2010; 30: 4209-4217.